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Our findings that PlGF is a cancer target and anti-
PlGF is useful for anticancer treatment have been
challenged by Bais et al. Here we take advantage of
carcinogen-induced and transgenic tumor models
as well as ocular neovascularization to report further
evidence in support of our original findings of PlGF as
a promising target for anticancer therapies. We
present evidence for the efficacy of additional anti-
PlGF antibodies and their ability to phenocopy
genetic deficiency or silencing of PlGF in cancer
and ocular disease but also show that not all anti-
PlGF antibodies are effective. We also provide addi-
tional evidence for the specificity of our anti-PlGF
antibody and experiments to suggest that anti-PlGF
treatment will not be effective for all tumors and
why. Further, we show that PlGF blockage inhibits
vessel abnormalization rather than density in certain178 Cell 141, 178–190, April 2, 2010 ª2010 Elsevier Inc.tumors while enhancing VEGF-targeted inhibition in
ocular disease. Our findings warrant further testing
of anti-PlGF therapies.INTRODUCTION
Placental growth factor (PlGF) is a VEGF homolog. Studies
in independently generated PlGF/ lines identified a role for
PlGF in ischemic, inflammatory, and malignant disease (Carme-
liet et al., 2001; E. Cheung et al., IOVS 2009;50:ARVO E-Abstract
2943; Fischer et al., 2008; Luttun et al., 2002a; Van Steenkiste
et al., 2009). PlGF induces responses in endothelial, malignant,
immune, and other cells and binds to Flt1 (Fischer et al., 2008).
Although Flt1may act as a trap for VEGF, it also transmits signals
in response to PlGF via its tyrosine kinase (TK) domains (Land-
gren et al., 1998). The role of Flt1 in cancer remains controversial,
but most studies report that Flt1 inhibition/silencing reduces
tumor growth in preclinical models. In mice expressing Flt1
without TK activity (Flt1-TK/), tumor growth and metastasis
are inhibited (Hiratsuka et al., 2002) or not affected (Dawson
et al., 2009).
Clinical studies show that PlGF levels correlatewith poor prog-
nosis of various cancers, including hepatocellular, colorectal,
renal, and other cancers (Fischer et al., 2008; Ho et al., 2006),
though PlGF is also epigenetically silenced (Xu and Jain, 2007).
PlGF levels are upregulated in cancer patients treated with
VEGF inhibitors (Willett et al., 2005). Moreover, PlGF expression
in tumor or stroma promotes cancer (Marcellini et al., 2006).
We showed that the anti-PlGF monoclonal antibody (mAb)
5D11D4 slows tumor growth in preclinical models, in part by
blocking angiogenesis and inflammation (Fischer et al., 2007).
However, anti-PlGF mAbs generated by Bais et al. were ineffec-
tive in mouse tumor models (Bais et al., 2010), questioning
whether the activity of 5D11D4 could be reproduced by indepen-
dently generated anti-PlGF mAbs. Also, issues were raised
about the dose and whether the effects of 5D11D4 were related
to off-target activity. Furthermore, Bais et al. argued that insuffi-
cient genetic evidence supported a role for PlGF in cancer, over-
all questioning the therapeutic value of anti-PlGF strategies
(Bais et al., 2010). Here, we provide genetic evidence for
a disease-candidate role of PlGF and underscore the potential
of anti-PlGF therapy in cancer by using complementary genetic
and pharmacological tools to eliminate, silence, or inhibit PlGF in
spontaneous tumor models. We also characterized via which
underlying mechanisms loss/inhibition of PlGF blocked tumori-
genesis. To obtain independent confirmation, other groups
than those involved in our original study (Fischer et al., 2007)
contributed autonomously.
RESULTS
Role of PlGF in Carcinogen-Induced Skin
Epithelial Tumor Model
We first explored whether loss of PlGF inhibits growth and angio-
genesis in a carcinogen-induced skin epithelial tumor model.
PlGF levels were low in healthy skin, acutely upregulated by
phorbol 12-myristate 13-acetate (PMA) (pg/mg: 13 ± 1 for control
versus 55 ± 6 after PMA; n = 12–6; p < 0.005), and chronically
elevated in small and large papillomas (pg/mg: 145 ± 49 and
192 ± 18; n = 5; p < 0.001). Formation of skin papillomas and
associated neovessels was delayed in PlGF/ mice (Figures
1A–1D). The average latency after the first PMA application
was 3 weeks longer in PlGF/ mice, and by 20 weeks, 94% of
wild-type (WT) mice but only 59% of PlGF/ mice developed
tumors (Figures 1E and 1F). PlGF/ mice formed 66% fewer
papillomas per mouse. Similar effects were observed for large
papillomas (>3 mm). In PlGF/ mice, the first large papilloma
developed 4 weeks later than in WT mice (Figures 1G and 1H).
At 20 weeks, the incidence of large papillomas was 50% in WT
mice but only 29% in PlGF/ mice, and the number of large
papillomas per mouse was decreased by 80%. Loss of PlGF
impaired the growth of neovessels in healthy skin around the
tumors (Figures 1B and 1D). Within papillomas, PlGF deficiency
did not affect vessel densities but reduced their size by 65% and
55% in small and large papillomas, respectively (n = 5; p < 0.05),
whereas the accumulation of macrophages, mast cells, or T cells
was not affected (not shown).Antitumor Activity of the Mouse Anti-Human
PlGF mAb 16D3
To extend the genetic evidence for a role of PlGF in cancer, we
also sought additional pharmacological evidence for a thera-
peutic potential of anti-PlGF in cancer and therefore evaluated
if the mouse anti-human PlGF mAb 16D3 (dissociation constant
[KD] = 12 pM for human PlGF-1) could reproduce the anticancer
activity of 5D11D4; this mAb was generated independently of
5D11D4 by immunizing PlGF/ mice with human PlGF-2.
Delivery of 16D3 dose-dependently elevated plasma 16D3 levels
(Figure S1A available online). At 12.5 mg/kg, 23/wk, 16D3
inhibited growth of MDA-MB-435 tumors in immunocompro-
mised mice by 40% (mm3: 1670 ± 194 for control versus 998 ±
210 for 16D3; n = 12; p = 0.03). 16D3 also inhibited the growth
of human pancreatic DanG xenografts (Figures S1B–S1D) and
cancer-associated cachexia (loss in body weight: 14% in control
versus 7% in 16D3; n = 9–10; p = 0.04). Both tumors produced
human PlGF (pg/mg protein in tumor lysates: 19 ± 5 for MDA-
MB-435; n = 12 and 103 ± 37 for DanG; n = 11).
PlGF Blockage Retards Hepatocellular
Carcinoma Growth
We then used two hepatocellular carcinoma (HCC) models to
characterize more extensively the effects and mechanisms
of PlGF blockage. To exclude that germline PlGF deficiency
induces compensatory changes that favor tumor inhibition
independently, we tested whether conditional PlGF silencing
inhibited growth of HCC. In the first model, transgenic expres-
sion of an SV40 T-antigen oncogene induced hyperplasia/
dysplasia (4–8 weeks), nodular adenoma (12 weeks), and diffuse
carcinoma (>16 weeks) (Dupuy et al., 2003). PlGF was undetect-
able in healthy hepatocytes but apparent in HCC, whereas Flt1
was upregulated in macrophages, Kupffer cells, and vessels
(not shown). By RT-PCR, PlGF transcripts were upregulated to
295% ± 28% of normal levels in adenomas (n = 4; p < 0.05).
Hepatic PlGF was silenced by treating HCC mice from 8 to
15 weeks with PlGF-specific siRNA, reducing PlGF protein
levels by 60% ± 8% (n = 5; p < 0.05). Despite incomplete
PlGF silencing, hepatomegaly was reduced, with the largest
inhibition when PlGF expression and macrophage infiltration
were maximal (see below) (Figure 1I); fewer and smaller tumor
nodules were present at 15 weeks (superficial nodules 0.5–1 cm
and >1.0 cm: 12.7 ± 2.9 and 6.0 ± 0.7 in untreated versus 12.0 ±
1.4 and 4.7 ± 1.1 in control siRNA, and 1.0 ± 0.7 and 0 ± 0 in
PlGF-specific siRNA, n = 3; p < 0.005; Figures 1J–1M).
We also used a carcinogen-induced HCC model by treating
mice with diethylnitrosamine (DEN), which causes fibrosis and
dysplastic lesions at 16 weeks and hypervascularized tumors
by 25 weeks. Hepatic PlGF levels were not acutely upregulated
by DEN (not shown) and remained initially low (pg/mg: 2.9 ± 0.7
in healthy versus 1.5 ± 0.4 after 4 weeks DEN; n = 6; p = not
significant [NS]) but increased to 423 ± 77 pg/mg in end-stage
tumor nodules (n = 6; p < 0.05). After 30 weeks of DEN treatment,
58% of WT mice (n = 24) but only 5% of PlGF/ mice (n = 21)
succumbed (p = 0.002, log rank) and fewer tumor nodules
were present in PlGF/ mice (nodules/liver: 17.9 ± 2.2 in WT
versus 5.9 ± 2.4 in PlGF/; n = 18; p = 0.002). When WT mice
with established HCC were treated with 5D11D4 (20 mg/kg;Cell 141, 178–190, April 2, 2010 ª2010 Elsevier Inc. 179
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Figure 1. Reduced Papilloma Formation and HCC upon PlGF Blockage
(A–D) Skin papillomas from external (A and C) or internal view (B and D) in PlGF/ (C and D) and WT mouse (A and B). Asterisks and arrowheads indicate
corresponding anatomical tumor locations.
(E–H) Incidence (E and G) and number of papillomas per mouse (F and H) (n = 19–20; p < 0.01).
(I) Echographic measurement of liver volume in healthy mice and in HCC mice, untreated or treated with PlGF-specific or control siRNA (mean ± SEM; n = 6–8;
*p < 0.05); healthy liver volumes: 0.74 ± 0.05, 0.8 ± 0.1, 0.88 ± 0.06, and 0.72 ± 0.05 cm3 at 8, 10, 12, and 14 weeks (n = 6).
(J–M) Micrograph of livers from healthy (J) or HCC mice (K–M), untreated (K), control siRNA-treated (L), or PlGF-specific siRNA-treated (M).
See also Figure S1.23/wk) from 25 weeks onward for 5 weeks, 45% of mice
receiving control IgG died whereas only 23% died in the
5D11D4 group (n = 23–25; p < 0.05). Also, 5D11D4-treated mice
developed fewer nodules per liver (nodules, all sizes: 21.6 ±
2.9 after control IgG versus 11.1 ± 2.6 after 5D11D4; n = 15;
p = 0.02). After 10 weeks of mAb treatment, mortality was
90% in the control group, but it was only 41% after 5D11D4
(n = 11; p < 0.05).
PlGF Blockage Inhibits Arterialization and Vessel
Abnormalization in HCC
In contrast to the largely portal venous blood supply in healthy
livers, the hepatic arterial network expanded substantially in
HCC (Figures 2A and 2B), giving rise to the formation of unpaired
arteries, i.e., large vessels with a mural coat of smooth muscle
actin (SMA)+ cells that are not accompanied by a bile duct
(Fernandez et al., 2009). In the transgenic model, PlGF silencing
abrogated arterialization, scored arteriographically (Figures 2C–
2E) and histologically (lumen size of unpaired arteries: 293 ±
72 mm2 in ctrl-siRNA versus 70 ± 16 mm2 in PlGF-siRNA; n = 4;180 Cell 141, 178–190, April 2, 2010 ª2010 Elsevier Inc.p < 0.05). In the DEN model, 5D11D4-treated HCC livers con-
tained fewer and smaller unpaired arteries (SMA+ unpaired
vessels: relative area in % of area analyzed and number/mm2:
5.8 ± 1.0 and 11.3 ± 2.9 after IgG versus 1.4 ± 0.3 and 6.3 ±
0.3 after 5D11D4; n = 7–3; p < 0.001 and p < 0.05; Figures
2F–2H).
Within HCC nodules, PlGF blockage did not alter capillary
density, when counting each branch or profile as a separate
vessel (Figures S2A and S2B). However, given that hypoxia stim-
ulates HCC growth (Wu et al., 2007) and that microvascular
density does not always provide insight into vessel function
(Mazzone et al., 2009), we analyzed other vascular parameters,
determining tumor oxygenation. First, we noticed that intercapil-
lary distances were larger and more variable in IgG-treated HCC
than in healthy liver (Figures 2I, 2J, and 2O), consistent with
reports that rapidly proliferating HCCcells outgrow their vascular
supply and thereby become hypoxic (Wu et al., 2007). In fact,
large avascular clusters of malignant HCC cells were often found
amidst a chaotic capillary network (Figure 2J). In contrast, in
PlGF-blocked HCC, intercapillary distances were still variably
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Figure 2. Mechanisms of Anti-HCC Activity by PlGF Blockage
(A–D) Micro-angiography of hepatic arterial supply in healthy (A), untreated HCC (B), control siRNA-treated HCC (C), and PlGF-silenced HCC (D) mice.
(E) Quantification of hepatic arterial network in healthy (white bar), untreated HCC (dark gray), control siRNA-treated HCC (light gray), and PlGF-silenced HCC
(blue) mice (AU: absolute pixel unit,&) (n = 4; *p < 0.05).
(F–H) SMA staining, revealing a portal triad with paired hepatic artery in a healthy liver (F), large, smooth muscle cell-coated unpaired arteries (asterisks) in HCC
mice treatedwith IgG (G), and a portal triad and small unpaired artery (asterisk) in HCC liver after 5D11D4 (H). Black arrowhead (bile duct); blue arrowhead (hepatic
paired artery); PV (portal vein).
(I–K) Immunostaining for the endothelial marker endoglin, showing portal vein (PV) and central vein (CV) amidst a sinusoidal network in healthy liver (I); black
arrowhead (bile duct); blue arrowhead (hepatic paired artery). In IgG-treated HCC nodules, the capillary network is chaotically organized, with tortuous vessels
and cords, laying at large distances from each other (J), in contrast to themore regular pattern, size, and shape of capillaries and shorter intercapillary distances in
5D11D4-treated HCC (K).
(L–N) Immunostaining for SMA, showing undetectable expression in HSCs around sinusoids in healthy liver (L). In HCC, tumor capillaries (red arrowhead) are
surrounded by strongly SMA+-stained HSCs in IgG-treated mice (M) but not in 5D11D4-treated mice (N).
(O) Histogram of intercapillary distances, showing shorter distances in 5D11D4-treated HCC; values in healthy liver are shown for comparison.
(P) Mac-3+ macrophage infiltration in tumors of HCC mice treated with control (gray) or PlGF-specific siRNA (blue) (n = 8; *p < 0.05).
Bars: 100 mm (F–K); 20 mm (L–N). Data are mean ± SEM. See also Figure S2 and Table S1.enlarged but less extensively than in control HCC, thereby
creating a more uniform vascular pattern (Figures 2K and 2O).
Second, PlGF blockage counteracted tumor capillary abnorm-
alization, which also determines tumor oxygenation (Mazzone
et al., 2009). In HCC nodules, sinusoids lose their characteristics
anddevelop into capillaries (‘‘sinusoidal capillarization’’) (Fernan-
dez et al., 2009). Typical for HCC, capillaries become surrounded
by activated hepatic stellate cells (HSCs), which express
increased levels of SMA, deposit matrix, and release angiogenic
and tumorigenic factors (Johnson et al., 1998). These changes
increase the resistance to blood flow and impede oxygendelivery, further aggravating hypoxia (Fernandez et al., 2009;
Paternostro et al., 2010). A smaller fraction of capillaries was
surrounded by SMA+ HSCs in PlGF-blocked HCC nodules
(SMA+ area around capillaries, %: 5.9 ± 1.3 after IgG versus
2.2 ± 0.6 after 5D11D4; n = 6–7; p = 0.02; Figures 2L–2N).
Furthermore, several capillaries in control HCC nodules had
an abnormal shape and size; although approximately half of
them had a regular patent lumen, others were present as cords
without lumen, and a smaller fraction was very tortuous (Figures
2I and 2J). PlGF blockage partially normalized their abnormal









Figure 3. Resistance of Rip1Tag2 Tumors
and Evidence for Specificity of 5D11D4
(A–D) The number (A and C) or total volume (B and
D) of tumors per mouse were not affected by
loss (A and B) or inhibition of PlGF by 5D11D4
(50 mg/kg; 33/week) (C and D) (n = 7–8); tumor
growth in PlGF+/:Rip1Tag2 and PlGF+/+:Rip1-
Tag2 mice was not different.
(E–I) Intramuscular AAV-PlGF gene transfer-
induced angiogenesis (F), which is blocked by
5D11D4 (G) but not by DC101 (H); panel E: control;
panel I: quantification of the microvascular density
(mean ± SEM; n = 5; *p < 0.05 versus control;
#p < 0.05).
(J–N) Intramuscular AAV-VEGF gene transfer-
induced angiogenesis (K), which is not affected
by 5D11D4 (L) but is reduced by DC101 (M);
panel J: control; panel N: quantification of the
microvascular density (mean ± SEM; n = 3; *p <
0.05 versus control; #p < 0.05).
Bars: 50 mm. See also Figure S3.were tortuous or cords and had a more normal appearance
(tortuous vessels/mm2 and cords/mm2: 44 ± 4 and 237 ± 21 in
IgG versus 22 ± 2 and 181 ± 15 in 5D11D4; n = 4–5; p < 0.001
and p = 0.05; Figures 2J and 2K). These changes were function-
ally relevant, as PlGF-blocked HCC nodules expressed lower
levels not only of HIF-2a (HIF-2a+ area, % of nodular area:
28.1 ± 4.3 for IgG versus 14.6 ± 2.6 for 5D11D4; n = 4–5;
p < 0.05) but also of other hypoxia-inducible genes (Table S1).
Moreover, in line with reports that hypoxia promotes HCC
growth, proliferation of HCC cells was higher in avascular clus-
ters (IgG) than in vascular regions with short intercapillary
distances (5D11D4) (PCNA+ cells/mm2: 90 ± 18 after IgG versus182 Cell 141, 178–190, April 2, 2010 ª2010 Elsevier Inc.36± 2 after 5D11D4; n = 4; p = 0.02). Addi-
tional analysis showed that activated
HSCs are a source of proangiogenic
PlGF, and that PlGF is amitogen and che-
moattractant for these cells but not for
hepatoma cell lines (not shown). Finally,
PlGF blockage reduced hepatic macro-
phage numbers in the transgenic (Fig-
ure2P) andcarcinogenmodel (not shown).
PlGF Blockage or Deficiency Does
Not Inhibit Rip1Tag2 Growth
We intercrossed the transgenic Rip1Tag2
model of pancreatic b cell carcino-
genesis with PlGF/mice. No genotypic
differences were observed between
Rip1Tag2 3 PlGF+/ and Rip1Tag2 3
PlGF/ mice in tumor incidence or
burden (Figures 3A and 3B) or staging
(Figure S3A), despite detectable PlGF
expression in WT tumors (Figure S3B).
As this tumor growth is independent of
PlGF, we used it to test whether 5D11D4
inhibits tumorigenesis via off-target activ-ities. Therefore, 9-week-old transgenics bearing angiogenic
tumors were treated with 5D11D4 (50 mg/kg; 33/week) for
3 weeks until end-stage. Treatment with 5D11D4 failed to
affect tumor growth or incidence in Rip1Tag2 mice (Figures 3C
and 3D), consistent with the absence of non-PlGF effects on
tumorigenesis. That 5D11D4 blocks PlGF specifically without
off-target effects was confirmed in additional experiments.
Indeed, angiogenesis induced by PlGF gene transfer in PlGF/
mice was selectively blocked by 5D11D4 but not by the anti-
Flk1/VEGFR-2 mAb DC101 (Figures 3E–3I), whereas DC101 but




Figure 4. Mechanisms of PlGF Blockage in
Rip1Tag2 Tumors
(A and B) Quantification of intratumoral vessel density of
tumors from Rip1Tag2:PlGF+/ and Rip1Tag2:PlGF/
mice (n = 7) (A) and of tumors from Rip1Tag2mice, treated
with control IgG or 5D11D4 (n = 7) (B).
(C and D) Quantification of neutrophil infiltration in tumors
fromRip1Tag2:PlGF+/ andRip1Tag2:PlGF/mice (n = 7)
(C) and in tumors from Rip1Tag2mice, treated with control
IgG or 5D11D4 (n = 7) (D). Data are mean ± SEM (C and D).Wealso analyzedwhyRip1Tag2 tumorswere resistant to PlGF
blockage. Notably, tumor angiogenesis was not affected by loss
or inhibition of PlGF (Figures 4A and 4B). In line with findings
that neutrophils mediate the tumor angiogenic switch in this
model (Nozawa et al., 2006), infiltration of myeloid cells (primarily
neutrophils) was not affected by PlGF blockage (Figures 4C and
4D), likely explaining the refractoriness of this model to PlGF
blockage.
5D11D4 Inhibits Choroidal Neovascularization
by Blocking PlGF
Bais et al. questioned the specificity of 5D11D4 in targeting PlGF
and criticized the use of a single anti-PlGFmAb clone (Bais et al.,
2010). To address these questions, we also used a model of
choroid neovascularization (CNV). Three days after laser injury,
choroidal PlGF levels were upregulated (pg/mg: 168 ± 12 in non-
injured versus 343 ± 18 in lasered choroids; n = 3; p < 0.05),
whereas Flt1 was detected in neovessels and stromal cells
(Figure S4A). 5D11D4 accumulated in CNV lesions upon intra-
peritoneal injection (Figure S4B). Quantification of CNV upon
perfusion with FITC-conjugated dextran 14 days after lasering
showed that 5D11D4 dose-dependently inhibited CNV, with
a maximal effect at 25 mg/kg, 33/week (Figures 5A–5C).
A comparable inhibition of 60% ± 6% was obtained with
25mg/kg, 23/week (n = 10; p = NS versus 33/week), while intra-
vitreal injection was also effective (not shown). 5D11D4 also
inhibited CNV by 53% ± 10% (n = 3; p < 0.05) in Ccl2/ mice,
a model of age-related macular degeneration (AMD) that better
resembles the human condition.
Bais et al. questioned the specificity of 5D11D4 and suggested
that Fc-dependent effects might explain its activity (Bais et al.,
2010). We reasoned that if 5D11D4 would specifically block
PlGF, it should not inhibit CNV beyond the level induced by defi-Cell 14ciency of PlGF or its signaling receptor Flt1.
Loss of PlGF inhibited CNV, but additional
5D11D4 treatment did not further reduce CNV
lesions (Figure 5D). Likewise, CNV was inhibited
in Flt1-TK/mice (indicating that Flt1 signaling
is critical and Flt1 does not act as a VEGF-trap
alone), but 5D11D4 did not further reduce CNV
lesions in these mice (Figure 5E).
To assess whether the Fc-fragment of
5D11D4 was required, we generated 5D11D4/
Fab fragments (KD = 1.51 nM). At 100- to
400-fold molar excess, Fab inhibited the bindingof PlGF to Flt1 (IC50 = 1.1 nM), neutralized Flt1 tyrosine phos-
phorylation in response to PlGF (response above control:
217% for PlGF; 0% for PlGF + 5D11D4/Fab; 15% for PlGF +
5D11D4), and blocked the chemotactic activity of PlGF for
macrophages (migrated cells/optical field: 169 ± 42 for control;
11 ± 17 for 5D11D4; 0 for 5D11D4/Fab; n = 6; p < 0.05). Com-
pared to control IgG/Fab, intra-ocular injection of 5D11D4/
Fab inhibited CNV formation at 5 days by 41% (neovascular
area, 3103 mm2: 16.6 ± 2.0 after IgG/Fab versus 9.8 ± 1.7;
n = 51–43; p = 0.01). Similar data were obtained with recombi-
nant 5D11D4/Fab (KD = 0.57 nM) (not shown).
Other anti-mouse PlGF mAb clones were used to reproduce
the 5D11D4 data. Of two other mAbs that bound to PlGF with
high affinity and blocked binding of PlGF to Flt1 in vitro, 3C7A8
(KD = 3.4 nM) inhibited CNV, whereas 12H6B5 (KD = 4.3 nM)
only showed a tendency (Figure 5F), even despite the fact that
plasma levels were >100 mg/ml for all mAbs. Thus, certain anti-
PlGF mAb clones with proven blockage of PlGF binding to its
receptor in vitro may still not be able to block PlGF-driven
processes in vivo.
As an independent confirmation of 5D11D4’s specificity, we
tested whether 16D3 blocked human PlGF-driven CNV in vivo.
Whereas delivery of human PlGF-2 via osmotic minipump
(10 mg/week) increased CNV lesions in humanized PlGF/
mice, treatment with 16D3 (25 mg/kg; 33/week) reduced
CNV to levels similar to those in PlGF/ mice (Figure 5G).
Similar data were obtained when PlGF/mice were humanized
by intravenous injection of the adenoviral vector Ad.hPlGF2,
which elevated circulating human PlGF-2 plasma levels to 200–
300ng/ml.Byday14,Ad.hPlGF2 increasedCNV formation nearly
to levels in WT mice, yet delivery of 16D3 (25 mg/kg, 23/week,
resulting in plasma 16D3 titers of 100–300 mg/ml) completely




Figure 5. Inhibition of CNV by Anti-PlGF or PlGF Deficiency
In all panels, analysis was 14 days after lasering; mAb (33/week) was started 3 hr after lasering until sacrifice.
(A) Dose-dependent inhibition of CNV by 5D11D4 (n = 12/group; *p < 0.05).
(B and C) FITC-dextran flatmounts, revealing fewer choroidal neovessels after 5D11D4 (C) than control IgG (B).
(D) CNV was reduced in PlGF/ mice, but 5D11D4 treatment (25 mg/kg) did not further reduce CNV in PlGF/ mice (n = 10/group; *p < 0.05 versus WT,
control IgG).
(E) Flt-TK deficiency reduced CNV but 5D11D4 (25 mg/kg) did not further reduce CNV (n = 6/group; *p < 0.05 versus WT, IgG).
(F) Inhibition of CNV by anti-PlGF mAb 3C7A8, whereas 12H6B6 only exhibited a tendency (25 mg/kg) (n = 6/group; *p < 0.05).
(G) Delivery of human PlGF-2 (10 mg/week) stimulated CNV in PlGF/mice; hPlGF-driven CNV was blocked by 16D3 (25 mg/kg) (n = 5/group; *p < 0.05 versus
hPlGF-2 without 16D3).
Data are mean ± SEM. See also Figure S4.5D11D4 Enhances VEGF-Targeted Inhibitors
Bais et al. questioned whether anti-PlGF mAbs enhanced VEGF-
inhibitor treatment (Bais et al., 2010). We thus evaluated whether
5D11D4 enhanced the effect of VEGF inhibitors by testing
the anti-Flk1 mAb DC101. At a dose of 6.25 to 50 mg/kg
(33/week), DC101 inhibited CNV (Figures 6A–6C). In line with
tumor studies (Fischer et al., 2007), DC101 elevated plasma
PlGF levels 3 days after laser injury (pg/ml: 11 ± 1.1 after IgG
versus 330 ± 49 after DC101; n = 5; p < 0.05). Because of the
role of PlGF in CNV and its upregulation by DC101, we explored184 Cell 141, 178–190, April 2, 2010 ª2010 Elsevier Inc.whether 5D11D4 could partially substitute DC101 without
compromising DC101’smaximal effect. Compared tomonother-
apy with a low dose of 12.5 mg/kg DC101 or 25 mg/kg 5D11D4,
the combination of 5D11D4 plus DC101 reduced CNV formation
more extensively, i.e., comparably to the maximal dose of
DC101 monotherapy (Figure 6D). These substitution results in
the CNV model mimic those in previous cancer studies (Fischer
et al., 2007).
Additionally, we used hydroporation gene transfer to elevate
plasma levels of soluble Flk1 (sFlk1, which traps VEGF) to
A B C
D E
Figure 6. 5D11D4 Enhances Inhibition of CNV by VEGF Inhibitors
In all panels, analysis was 14 days after lasering; mAb (33/week) was started 3 hr after lasering until sacrifice.
(A) Dose-dependent inhibition of CNV by DC101 (n = 12/group; *p < 0.05).
(B and C) FITC-dextran choroidal flatmounts, revealing fewer perfused neovessels after DC101 (C) than control IgG (B).
(D) Partial replacement of DC101 with 5D11D4 yielded similar anti-CNV effect as maximal DC101 dose alone (n = 12/group; *p < 0.05 versus control; #p < 0.05
versus monotherapy); dose (mg/kg) of 5D11D4 and DC101 is indicated below each bar.
(E) Combination of 5D11D4 (25 mg/kg) plus gene transfer of sFlk1 (hydroporation 2 days before lasering) inhibited CNV more than either monotherapy (n = 8–11;
*p < 0.05 versus control; #p < 0.05 versus monotherapy).
Data are mean ± SEM.5.2 ± 1.5 mg/ml by day 5 (Davidoff et al., 2002). Compared to the
prominent anti-CNV effect of DC101, sFlk1 reduced CNV only
partially (Figure 6E). However, this intermediate inhibition
allowed us to explore whether 5D11D4 amplified the anti-CNV
effect of sFlk1. Indeed, CNV was inhibited more extensively by
the combination of 5D11D4 plus sFlk1 than by either monother-
apy (Figure 6E). Thus, as observed in tumors (Fischer et al.,
2007), 5D11D4 enhanced the effect of a VEGF-trap.
5D11D4 Inhibits Ocular Angiogenesis and Inflammation
Bais et al. also criticized the ability of anti-PlGF mAbs to block
angiogenesis and inflammation (Bais et al., 2010). We thus
analyzed whether 5D11D4 and PlGF deficiency inhibited CNV
via similar mechanisms, as this would strengthen the conclu-
sion that the mAb acts via specific inhibition of PlGF and
not via off-target mechanisms. Since FITC-dextran only labels
perfused vessels, we analyzed all neovessels by staining
choroidal cross-sections for the endothelial marker CD31. At
25 mg/kg, 5D11D4 reduced total vessel area and vessel density
comparably as in PlGF/ mice (Figures 7A and 7B), indicating
that 5D11D4 phenocopied the angiostatic PlGF/ mecha-
nisms, not only qualitatively but even (nearly) quantitatively.
DC101 similarly inhibited vessel area and density (Figures 7A
and 7B).To characterize the vascular phenotype further, we used scan-
ning electron microscopy (SEM) to visualize microvascular
corrosion casts. In WT mice, a dense network of choroidal neo-
vessels sprouted from the adjacent healthy tissue into the lesion
(Figures 7C and 7D). By contrast, in 5D11D4-treated WT and in
PlGF/ mice, fewer neovessels sprouted and branches only
formed short aborted stumps (Figures 7E–7H). DC101 induced
a distinct defect, characterized by fewer sprouts with only
a few side branches and spiky projections, and the endothelium
appeared almost frozen (Figures 7I and 7J). Loss or inhibition of
PlGF also comparably blocked choroidal vessel leakage (Figures
S5A and S5B; not shown). Macrophage infiltration was also
inhibited by PlGF blockage. In WT mice, 5D11D4 reduced the
F4/80+ area, whereas DC101 had no effect (Figures 7K–7M); this
may explain why DC101 reduced lesion thickness less exten-
sively than 5D11D4 (not shown). The F4/80+ area was compa-
rably reduced in PlGF/ mice (Figure 7K).
DISCUSSION
Bais et al. questioned the disease role of PlGF and therapeutic
potential of anti-PlGF mAbs (Bais et al., 2010). First, they
indicated that there is insufficient genetic evidence for a role













Figure 7. Mechanisms of CNV Inhibition by PlGF Blockage
Analysis at days 14 (A–J) or 5 (K–M) after lasering; mAb treatment (33/week) started 3 hr after lasering until sacrifice.
(A and B) PlGF deficiency and 5D11D4 (25 mg/kg) reduced CD31+ area (A) and vessel density (B) (n = 10; *p < 0.05 versus control). The antiangiogenic effect of
DC101 (25 mg/kg) is shown for comparison.
(C–J) SEM micrographs of CNV in WT (C and D), PlGF/ (E and F), 5D11D4-treated WT (G and H), and DC101-treated WT (I and J) mice. Dashed line: border
between laser-induced necrotic center (black hole) and adjacent healthy choroid, from where neovessels sprout. In WT mice, vessels of irregular size and shape
sprouted into the wound. By contrast, in PlGF/ and 5D11D4-treated WT mice, neovessels only formed aborted stumps, despite numerous spiky protrusions.
After DC101, neovessels appeared immobilized (‘‘frozen’’) and exhibited signs of pruning with few sprouts. Bars: 50 mm (C, E, G, and I); 10 mm (D, F, H, and J).
(K) Absence of PlGF or 5D11D4 (25 mg/kg) inhibits accumulation of F4/80+ macrophages in CNV, whereas DC101 is ineffective (n = 10/group; *p < 0.05).
(L and M) F4/80 immunostaining of CNV lesions, showing reduced macrophage infiltration after 5D11D4 (25 mg/kg) (L) as compared to IgG (M). Dashed lines:
borders of CNV lesion.
Data are mean ± SEM. See also Figure S5.
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carcinogen-induced HCC and papilloma formation, and that
PlGF silencing retards transgenic HCC, consistent with reports
that PlGF levels correlate with a poor outcome in HCC patients
(Ho et al., 2006). Moreover, silencing of tumor cell-derived
PlGF causes regression of pediatric brain tumors (R. Jain,
personal communication). Though our study provides initial
loss-of-function genetic evidence for a role of PlGF in sponta-
neous cancer models, caution is warranted to generalize the
role of PlGF in cancer, as Rip1Tag2 tumors are resistant.
A second concern was whether the 5D11D4 effects are
specific. Independent evidence argues that 5D11D4’s activity
is specific. First, the anticancer and anti-CNV effects by
5D11D4 and 16D3 are phenocopied by the loss of PlGF or Flt1
in the models studied. Similar findings were obtained indepen-
dently in pediatric brain tumors (R. Jain, personal communica-
tion). Even the lack of an effect of PlGF deficiency and 5D11D4
treatment on Rip1Tag2 tumors suggests that 5D11D4 does not
induce off-target effects. Furthermore, the safety profile of
5D11D4 in mice (Fischer et al., 2007) and of the humanized
anti-human PlGF mAb TB403 in humans (Lassen et al., 2009;
Riisbro et al., 2009) resembles the lack of disease development
in PlGF/ mice (Carmeliet et al., 2001). Overall, when PlGF/
and 5D11D4 effects were compared, 5D11D4 mimicked each
PlGF/ phenotype analyzed so far (Table S2), supporting a
specific activity of 5D11D4.
Another argument for the specificity of 5D11D4 is that delivery
of this mAb and loss of PlGF induced similar mechanisms, albeit
with contextual differences. For instance, angiogenesis was
inhibited comparably by loss or inhibition of PlGF in CNV. In
HCC, silencing or inhibition of PlGF reduced arterialization and
tumor vessel abnormalization. Angiogenic defects were also
observed in papillomas, reminiscent of those seen after PlGF
loss or inhibition in implanted tumors and other diseases (Carme-
liet et al., 2001; Fischer et al., 2007) aswell as in ischemic retina in
an independently generated PlGF/ model (E. Cheung et al.,
IOVS 2009;50:ARVO E-Abstract 2943). Arterialization defects
in PlGF-blocked HCC resemble those in portal hypertension
and limb revascularization in PlGF/ mice (Carmeliet et al.,
2001; Van Steenkiste et al., 2009). Also, in CNV and HCC, loss,
silencing, or inhibition of PlGF impaired macrophage accumula-
tion, as in skin inflammation and atherosclerosis (Oura et al.,
2003; Roncal et al., 2010). In papilloma, PlGF deficiency did
not prevent macrophage accumulation, but because myeloid
cells promote release of proangiogenic PlGF, blockage of
macrophage-derived PlGF can contribute to impairing papilloma
growth. Moreover, effects of PlGF blockage on macrophage
polarization should not be excluded (C. Rolny, personal commu-
nication). Our findings that PlGF blockage does not necessarily
need to affect microvascular density or macrophage counts in
order to inhibit growth of certain tumors highlight the context-
dependent multitasking activity of PlGF and the need to analyze
vessel size or function as well. Obviously, in other situations, for
instance when 5D11D4 treatment of a chronic disease is initiated
at advanced stages, short-term PlGF inhibition may induce
different mechanisms than permanent PlGF gene inactivation.
A third concern was that only a single anti-PlGF mAb clone
was used. Chemical PlGF blockage inhibits growth and metas-
tasis of xenografts (Taylor and Goldenberg, 2007) and anti-PlGF antiserum blocks PlGF-induced leakage (Carmeliet et al.,
2001). Here, the anticancer/anti-CNV activity of 5D11D4 was
reproduced by independently generated anti-mouse (3C7A8)
and anti-human (16D3) PlGF mAbs. Similar to the Bais study
(Bais et al., 2010), we also obtained mAb clones that recognized
PlGF and blocked its binding to Flt1 in vitro but lacked efficacy
in vivo. The precise reasons heretofore remain to be defined,
but an outstanding question is whether immunization of PlGF/
mice with ‘‘foreign’’ PlGF might have yielded mAbs with distinct
properties for inhibiting PlGF in situ. Whether differences in
physicochemical properties, posttranslational modifications, or
other alterations may influence their efficacy also remains to be
determined. An increased affinity and potency of anti-VEGF
mAbs in vitro did also not directly correlate with antiangiogenic
potency or efficacy in vivo (Gerber et al., 2007).
It is also relevant to note that we identified a spontaneous
tumor model that was refractory to PlGF loss or inhibition, indi-
cating that PlGF is not a disease-promoting factor in all tumors
and that other tumor models could be refractory to anti-PlGF
as well. The resistance of the Rip1Tag2 model to PlGF blockage
is likely due in part to the inability of PlGF loss or inhibition to
block the infiltration of neutrophils, key mediators of the angio-
genic switch in this model (Nozawa et al., 2006). As other tumors
can be resistant, it will be relevant to study the underlying mech-
anisms and identify predictive biomarkers.
Fourth, the dose of 5D11D4 was criticized. Initially, we used
50 mg/kg, even though signs of efficacy were noticed at
12.5 mg/kg (Fischer et al., 2007). This is higher than the dose
used for other mAbs against (un)related targets (1 to 10 mg/kg)
but comparable to the dose used for DC101 or anti-Flt1
(40 mg/kg). Anti-VEGFmAbs are used clinically at 5 to 15mg/kg.
In more recent studies, we obtained anti-disease activity in
atherosclerosis, CNV, and HCC with 5D11D4 at 20–25 mg/kg,
delivered only two times per week (Roncal et al., 2010). Further-
more, 16D3 inhibited human cancer xenografts at 12.5 mg/kg,
and statistically significant tumor growth inhibition has been
observed with the humanized anti-human PlGF mAb TB403 in
a human RCC xenograft at doses as low as 3 mg/kg (C. Rizzo,
personal communication). Disease stabilization for 12 months
has been observed with TB403 at 5 mg/kg in 2 out of 23 cancer
patients with advanced disease refractory to standard therapy
(Lassen et al., 2009; Riisbro et al., 2009).
Related to Bais’ remark that 5D11D4 is in vast excess of its
ligand (Bais et al., 2010), it is noteworthy that anti-VEGF also
circulates in vast excess over its ligand. Indeed, in cancer
patients and mice, comparable plasma levels were reported
for VEGF and PlGF (10 to 100 pg/ml) and for anti-VEGF and
anti-PlGF mAbs delivered at effective doses (300 to 600 mg/ml),
resulting in >106-fold excess of mAb over ligand (Gordon et al.,
2001; Lassen et al., 2009; Riisbro et al., 2009). Furthermore, it
should be noticed that in the gene transfer experiments, 16D3
blocked CNV, even though its plasma titers were only 103-fold
higher than circulating human PlGF levels.
Although we do not question the findings of Bais et al. (Bais
et al., 2010), we also do not have a unifying explanation, and
additional studies will be required to resolve the Matters Arising.
For instance, an outstanding question is how our PlGF/ data
can be reconciled with Flt1-TK/ data. Controversial findingsCell 141, 178–190, April 2, 2010 ª2010 Elsevier Inc. 187
on tumor growth in Flt1-TK/ mice will need to be resolved as
well (Dawson et al., 2009; Hiratsuka et al., 2002), and the fact
that Flt1-TK/ mice upregulate VEGF highlights the complexity
of this model (Wittko et al., 2009), cautioning against oversimpli-
fied interpretations of data in this model.
Even though HCC is a ‘‘hypervascular’’ cancer, it is character-
ized by hypoxia, and its growth is promoted by hypoxia
(Wu et al., 2007). Paradoxically, even though hypoxic HCC cells
try to improve their oxygenation by stimulating the arterial blood
supply, they impair oxygen delivery by inducing capillary ‘‘vessel
abnormalization’’ in tumor nodules. Moreover, because of their
aggressive nature, they outgrow their vascular supply, thereby
enlarging intercapillary distances and aggravating hypoxia.
This initiates a self-reinforcing vicious cycle of nonproductive
HCC vascularization, which impairs instead of improves tumor
oxygenation and promotes malignancy. By inducing vessel
normalization, PlGF blockage interrupts this cycle, creates
a less oxygen-deprived and oncogenic microenvironment, and
reduces the need for arterialization. Given that VEGF inhibitors
may fuel metastasis by evoking hypoxia (Loges et al., 2009),
the anti-abnormalization activity of anti-PlGF may offer a novel
mechanistic framework to combat HCC.
Anti-VEGF therapy offers improvement of vision in patients
with AMD but requires intravitreal injection with a risk of adverse
effects. The safety profile of anti-PlGF warrants further study if
systemic delivery of anti-PlGF mAbs can be used to partially
replace anti-VEGF in at-risk patients. Finally, results of phase I
clinical trials show that TB403 was well tolerated without
increased risk of adverse effects in healthy volunteers and
terminal cancer patients but with initial signs of disease stabiliza-
tion in 6 of 23 cancer patients (Lassen et al., 2009; Riisbro et al.,
2009). Future clinical studies will be required to assess the
therapeutic potential of anti-PlGF strategies in cancer and non-
oncology indications, but, by their very nature, such develop-
ments represent complex challenges.
EXPERIMENTAL PROCEDURES
Additional information is available in the Extended Experimental Procedures.
Animals
C57BL/6,Swiss, andnudemicewere fromCharlesRiver,Belgium;Balb/Cmice
from Harlan, Netherlands; Ccl2/ mice from Jackson Laboratory. PlGF/
mice were described (Carmeliet et al., 2001). Flt1-TK/ mice were provided
by M. Shibuya. Animal procedures were approved by ethical committees.
Monoclonal Antibodies
mAbs against murine or human PlGF-2 were generated in PlGF/mice. Fabs
were obtained by papain digestion; recombinant Fabs were generated by
coexpression of the heavy chain and light chain variable domain in E. coli
(see Extended Experimental Procedures). Kinetic analysis of antibody/ligand
was performed using surface plasmon resonance. mAb biotinylation was
performed using EZ-link Sulfo-NHS-LC-Biotin.
Tumor Mouse Models
Evaluation of tumor incidence and growth, immunostaining, and morphometry
of vascular, inflammatory, and other parameters are specified in the Extended
Experimental Procedures.
Skin Carcinogenesis Model
For tumor initiation, 25 mg 7,12-dimethylbenz[a]anthracene (Sigma) was
applied topically to shaved skin of 8-week-old female mice (129/Sv), followed188 Cell 141, 178–190, April 2, 2010 ª2010 Elsevier Inc.by weekly topical application of 5 mg PMA for 20 weeks (Hawighorst et al.,
2001). Lesions with a diameter >1 mm present for > 1 week were recorded
as a tumor.
Trangenic HCC Model
Male C57Bl6/ASV-B mice, expressing SV40 T-Ag in hepatocytes, developed
HCC (Dupuy et al., 2003). Control and PlGF siRNA (Dharmacon Custom
siSTABLE SMART pool; Perbio Sciences) were injected intraperitoneally
(i.p.) every 3 days from weeks 8 to 15 (2.5 mg/g).
DEN-Induced HCC Model
Five-week-old male WT and PlGF/mice (129/Sv) received weekly i.p. injec-
tions with DEN (35 mg/kg). Wild-type mice were treated with 5D11D4 or IgG
(20 mg/kg; 23/week).
Rip1Tag2 Mouse Model
Rip1Tag2 mice were crossed with PlGF/ mice (C57Bl/6) or treated with
50 mg/kg 5D11D4 or IgG for 3 weeks from 9 weeks. Tumor analysis of
Rip1Tag2:PlGF/ and Rip1Tag2:PlGF+/ littermates was performed at 12 and
13 weeks.
Tumor Xenografts
107 MDA-MB-435 cells were injected subcutaneously (s.c.) in 8-week-old
triple immunodeficient Beige Nude XIC NIHIII mice; 107 human pancreatic
DanG tumor cells were s.c. injected in 11-week-old female nu/nu mice. Mice
were randomized for treatment at 60 mm3 tumor volume. 16D3 or control
IgG were injected i.p. All analyses were as described (Fischer et al., 2007).
16D3 levels were measured by anti-mouse IgG ELISA using hPlGF-1-coated
plates.
Choroidal Neovascularization Model
CNV was induced in C57BL/6 mice by laser burn. Mice were injected i.p. with
5D11D4, DC101, or control IgG, 2–33/week until days 5 or 14, or intravitreally
with 5D11D4/Fab or control IgG/Fab on days 0 and 3. CNV was measured by
investigators masked to treatment and confirmed independently by investiga-
tors in three laboratories (VRC, UlG, and TG). For sFlk1 gene transfer, 40 mg of
a vector encoding sFlk1 or control was injected intravenously (i.v.). Plasma
sFlk1 was determined by immunoassay (R&D Systems). Groups involved ten
mice (unless otherwise stated) and experiments were repeated 33. Histology
and immunostaining were as described (Carmeliet et al., 1998; Fischer
et al., 2007; Luttun et al., 2002b). Eyes were enucleated after intracardial or
retrobulbar perfusion with FITC-conjugated dextran, flat mounted (left eye),
or processed for immunohistology (right eye). The CNV area, total lesion
area, and their ratio were analyzed using a Zeiss Axio Imager Z1 microscope
with macros (KS300 image analysis software) on FITC-perfused flat mounts.
Immunostainings for CD31, F4/80, PlGF, and Flt1, morphometric analysis of
neovascular area, vessel density, and inflammation, and SEM on choroidal
corrosion casts were performed as in the Extended Experimental Procedures.
PlGF levels in choroids were determined by ELISA (R&D Systems). To
humanize PlGF/ mice, human PlGF-2 protein or gene was administered
via osmotic minipumps (10 mg/week for 14 days) or adenoviral injection (3 3
109 pfu in 100 ml, i.v.); on day 2, eyes were lasered and mice were injected
i.p. every 2 days with 16D3 (25 mg/kg) or control IgG. Macrophage migration,
Flt1 phosphorylation, and limb muscle angiogenesis were performed as in the
Extended Experimental Procedures.
Statistics
All data are mean ± standard error of the mean (SEM). Statistical significance
was calculated by two-sided unpaired or paired (for body weight loss data)
Student’s t test (Prism). Tumor growth curves (tumor xenografts) were
analyzed using a general linear model (Univariate ANOVA), with correction
for the experiment (two independent experiments) or by two-way ANOVA
(SPSS). HCC mortality scores were analyzed by log rank test, and vessel
distance distribution scores by Chi-square. In the legends, the number of
mice refers to the size of the group shown in the representative experiment.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and two tables and can be found with this article online at doi:10.
1016/j.cell.2010.02.039.
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